What is the most appropriate next step in management for a 34-year-old woman with systemic lupus erythematosus on hydroxychloroquine who presents with jaundice, pruritus, fatigue, hepatomegaly, elevated bilirubin and liver enzymes, positive ANA, and liver biopsy showing interface hepatitis with plasma cells?

Autoimmune Hepatitis: Initiate Corticosteroid and Azathioprine Therapy Immediately

This patient has autoimmune hepatitis (AIH) and requires immediate immunosuppressive treatment with prednisolone plus azathioprine as first-line therapy. The clinical presentation—interface hepatitis with plasma cells on biopsy, markedly elevated transaminases (AST 654, ALT 734), hyperglobulinemia (43 g/L), and high-titer ANA (1:640)—establishes the diagnosis of AIH despite her underlying SLE 1, 2.

Diagnostic Confirmation

This patient meets definitive criteria for AIH:

• Histologic hallmark: Interface hepatitis with plasma cell infiltration on liver biopsy 1, 3
• Biochemical pattern: Predominantly hepatocellular injury (AST/ALT elevation >> alkaline phosphatase)
• Immunologic markers: Elevated IgG (reflected in hyperglobulinemia) and positive ANA 2
• Exclusion criteria met: Negative viral hepatitis serology 1

The coexistence of SLE and AIH represents an overlap syndrome, which is rare but well-documented 4, 5, 6. The liver biopsy findings are critical here—interface hepatitis with plasma cells strongly favors AIH over lupus hepatitis, which typically shows non-specific lobular inflammation without significant interface activity 7, 8.

Immediate Treatment Protocol

First-Line Immunosuppression

Start prednisolone 30 mg/day (or up to 1 mg/kg/day given severity) with plan to taper to 10 mg/day over 4 weeks as transaminases fall 1, 2. Add azathioprine 50 mg/day initially, increasing to maintenance dose of 1-2 mg/kg/day based on tolerance 1, 2.

The 2015 EASL guidelines explicitly state: "Predniso(lo)ne as initial therapy followed by the addition of azathioprine after two weeks is the first line treatment of AIH" 1. However, given this patient's bilirubin is 43 μmol/L (well below the 100 μmol/L threshold), azathioprine can be initiated immediately rather than delayed 1.

Critical Pre-Treatment Considerations

Before starting azathioprine:

• Check TPMT levels to exclude homozygote deficiency and reduce risk of severe myelosuppression 2
• Assess for G6PD deficiency given her hydroxychloroquine use, though this is more relevant for hemolysis risk 9
• Baseline complete blood count to document pre-existing cytopenia 2

Monitoring Strategy

Weekly monitoring for the first 4 weeks: liver enzymes, bilirubin, complete blood count, and glucose 2. The elevated random glucose (7 mmol/L) warrants particular attention as both corticosteroids and hydroxychloroquine can cause hypoglycemia 9.

After initial 4 weeks, reduce monitoring frequency to 1-3 monthly depending on response 2.

Management of Hydroxychloroquine

Continue hydroxychloroquine for her underlying SLE 10, 11. The 2024 KDIGO guidelines strongly recommend hydroxychloroquine for all SLE patients unless contraindicated, as it reduces flares, organ damage, and mortality 10.

However, immediately measure liver tests given the FDA warning about hydroxychloroquine-induced hepatotoxicity 9. The drug label specifically states: "Cases of hepatotoxicity have been reported...with marked elevations in transaminases (>20 times upper limit) within days to a month of hydroxychloroquine initiation" 9. While this patient has been on hydroxychloroquine chronically (making acute drug-induced liver injury less likely), the liver biopsy showing interface hepatitis with plasma cells is inconsistent with typical hydroxychloroquine hepatotoxicity and strongly supports AIH 12.

Treatment Goals and Expected Response

Target complete biochemical remission: normalization of transaminases AND IgG levels 1. Persistent elevation predicts relapse, ongoing histologic activity, progression to cirrhosis, and poor outcome 1.

Expected timeline:

• Transaminases should begin falling within 2 weeks 2
• Clinical symptoms (jaundice, pruritus, fatigue) should improve within 3-6 months 2
• 80-90% of patients achieve biochemical response 1, 2

When to Escalate Care

Contact a transplant center immediately if 2:

• Bilirubin continues rising despite treatment
• MELD score does not improve within 7 days
• Development of hepatic encephalopathy or ascites

The 2015 EASL guidelines are explicit: "Patients with acute severe AIH should be treated with high doses of intravenous corticosteroids (≥1 mg/kg) as early as possible. Lack of improvement within seven days should lead to listing for emergency liver transplantation" 1.

Common Pitfalls to Avoid

1. Do not delay treatment for repeat biopsy: The diagnosis is established; treatment should begin immediately 1, 2

2. Do not use budesonide: This patient has hepatomegaly with "bright coarse echogenicity" on ultrasound suggesting possible cirrhosis. Budesonide is contraindicated in cirrhotic patients due to impaired first-pass metabolism 1

3. Do not attribute liver disease solely to SLE: The liver biopsy findings of interface hepatitis with plasma cells are diagnostic of AIH, not lupus hepatitis 4, 5, 6, 7

4. Do not stop hydroxychloroquine without cause: Unless hepatotoxicity is definitively proven, continuing hydroxychloroquine is beneficial for her SLE 10

Long-Term Considerations

After achieving remission, consider repeat liver biopsy at 2 years to confirm histologic remission before attempting steroid taper 2. The 2011 BSG guidelines note that 55% of patients with normal transaminases still have interface hepatitis on biopsy 2.

Maintain azathioprine long-term as steroid-sparing agent, with prednisolone tapered to ≤7.5 mg/day or discontinued if possible 1, 11. The goal is lowest achievable disease activity with minimum steroid exposure to prevent damage accrual 11.